Vanguard Personalized Indexing Management LLC Acquires 16,823 Shares of Bristol Myers Squibb Company $BMY

Vanguard Personalized Indexing Management LLC raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 211,950 shares of the biopharmaceutical company’s stock after purchasing an additional 16,823 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Bristol Myers Squibb were worth $11,433,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at approximately $32,000. Finally, Garner Asset Management Corp bought a new position in Bristol Myers Squibb in the 4th quarter valued at approximately $35,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 1.4%

NYSE:BMY opened at $56.30 on Tuesday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a market cap of $114.97 billion, a PE ratio of 15.82, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a 50 day simple moving average of $57.67 and a two-hundred day simple moving average of $56.99.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the previous year, the firm posted $1.80 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, Bank of America lowered their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.